Genesen, established in 2018 and dedicated to improve the quality of people’s lives, is developing peptide-based drugs for the treatment of autoimmune / inflammatory diseases such as lupus, rheumatoid arthritis, and psoriasis.
We focus on developing innovative new drugs for diabetes, obesity, cancer, immune diseases and rare diseases by using our own platform technology to improve the lives of people who suffer from diseases.
We are committed to operating responsibility and gaining faith from the community. We are devoted to take leaps into the future with the spirit of creativity and innovation.
Genesen is passionate about giving back to the community through developing innovative new drugs. We sincerely appreciate you for your continued support in our endeavor.
Genesen CEO Sung Ho Lee